Prevention of Exercise-induced Asthma by a Fixed Combination of Disodium Cromoglycate plus Reproterol Compared with Montelukast in Young Patients

Lecheler, Josef; Pfannebecker, Bernhard; Nguyễn, Duc Tung; Petzold, U.; Munzel, Ullrich; Kremer, Hans-Joachim; Maus, Joachim

doi:10.1055/s-0031-1296511

Cited by 1 publication

(1 citation statement)

References 17 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Lecheler and colleagues compared a fixed combination of disodium cromoglycate plus reproterol (DSCG/REP) to montelukast in a group of children aged 11–18 years and found that DSCG/REP before exercise was superior in preventing EIA 73. Significant limitations in this study are noted including small numbers and an open design among others.…”

Section: Efficacy Studies In Children Adolescents and Adultsmentioning

confidence: 95%

Exercise-induced asthma: critical analysis of the protective role of montelukast

Carver¹

2009

JAA

View full text Add to dashboard Cite

Exercise-induced asthma/exercise-induced bronchospasm (EIA/EIB) is a prevalent and clinically important disease affecting young children through older adulthood. These terms are often used interchangeably and the differences are not clearly defined in the literature. The pathogenesis of EIA/EIB may be different in those with persistent asthma compared to those with exercise-induced symptoms only. The natural history of EIA is unclear and may be different for elite athletes. Leukotriene biology has helped the understanding of EIB. The type and intensity of exercise are important factors for EIB. Exercise participation is necessary for proper development and control of EIA is recommended. Symptoms of EIB should be confirmed by proper testing. Biologic markers may also be helpful in diagnosis. Not all exercise symptoms are from EIB. Many medication and nonpharmacologic treatments are available. Asthma education is an important component of managing EIA. Many medications have been tested and the comparisons are complicated. Montelukast is a US Food and Drug Administration-approved asthma and EIB controller and has a number of potential advantages to other asthma medications including short onset of action, ease of use, and lack of tolerance. Not all patients improve with montelukast and rescue medication should be available.

show abstract

Section: Efficacy Studies In Children Adolescents and Adultsmentioning

confidence: 95%

Exercise-induced asthma: critical analysis of the protective role of montelukast

Carver¹

2009

JAA

View full text Add to dashboard Cite

show abstract

Prevention of Exercise-induced Asthma by a Fixed Combination of Disodium Cromoglycate plus Reproterol Compared with Montelukast in Young Patients

Abstract: Inhalation of DSCG/REP before exercise provides significantly better protection against EIA than three days treatment with MON.

Cited by 1 publication

References 17 publications

Exercise-induced asthma: critical analysis of the protective role of montelukast

Exercise-induced asthma: critical analysis of the protective role of montelukast

Contact Info

Product

Resources

About